A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi
A phase 1/2 trial of Englumafusp alfa, Obinutuzumab, Glofitamab in non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT04077723 by Hoffmann-La Roche, with 498 participants planned, started 2019-08-13 and due to reach its primary completion in 2027-03-31. Interventions recorded: Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat
Shares Tocilizumab, Glofitamab, Obinutuzumab, Roche / Genentech.
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Tocilizumab, Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu
Shares Glofitamab, Obinutuzumab, Roche / Genentech, Non-Hodgkin lymphoma (all types).
- TrialAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Shares Tocilizumab, Glofitamab, Obinutuzumab.
- TrialA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Shares Tocilizumab, Roche / Genentech, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Shares Tocilizumab, Glofitamab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Shares Tocilizumab, Roche / Genentech, Non-Hodgkin lymphoma (all types).